Literature DB >> 2499638

Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas.

D E Milenic1, J M Esteban, D Colcher.   

Abstract

Immunoglobulin fragments, whether of polyclonal or monoclonal antibodies, offer a number of advantages over the intact immunoglobulin. The generation of immunoreactive fragments from monoclonal antibodies (MAb) is not always a straightforward task. Both pepsin and papain can be used to digest MAb to a bivalent molecule with a Mr of 100,000. However, pepsin pepsin digestions does not always result in immunoreactive fragments and a stable consistent product by papain digestion is often difficult to obtain. MAb B72.3 is an example of both situations. MAb B72.3 reacts with a glycoprotein (TAG-72) with a molecular weight greater than 10(6). MAb B72.3 has been shown to exhibit a high degree of selective reactivity with colon, breast and ovarian carcinomas and has been used for radioimmunodiagnosis in model systems and in clinical trials. A third enzyme, bromelain, in the same family of sulfhydryl proteases as papain, has been used to generate a fragment of MAb B72.3, with a Mr of approximately 100,000. The bromelain-generated fragment of MAb B72.3 retained 100% immunoreactivity as measured in competitive solid-phase radioimmunoassays and could be generated with consistent results from one preparation to another. Both the bromelain- and papain-generated fragments were radiolabelled with 125I without significant loss of the MAb's reactivity to tumor extracts. Differences were observed between the bromelain- and papain-generated fragment when compared in vivo. Fragmentation of MAb B72.3 with bromelain has yielded a superior bivalent fragment for radioimmunolocalization.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499638     DOI: 10.1016/0022-1759(89)90291-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment.

Authors:  D J King; J R Adair; S Angal; D C Low; K A Proudfoot; J C Lloyd; M W Bodmer; G T Yarranton
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

2.  In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive Cancers.

Authors:  Karen J Wong; Kwamena E Baidoo; Tapan K Nayak; Kayhan Garmestani; Martin W Brechbiel; Diane E Milenic
Journal:  EJNMMI Res       Date:  2011-06-07       Impact factor: 3.138

3.  Crystallization and preliminary X-ray analysis of four cysteine proteases from Ficus carica latex.

Authors:  Sarah Haesaerts; John Alexander Rodriguez Buitrago; Remy Loris; Danielle Baeyens-Volant; Mohamed Azarkan
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-03-20       Impact factor: 1.056

4.  Exploration of a F(ab')2 Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy.

Authors:  Diane E Milenic; Young-Seung Kim; Kwamena E Baidoo; Karen J Wong; Rachel Barkley; Jose Delgado; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2018-06       Impact factor: 3.099

5.  Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.

Authors:  Jonathan G Sham; Forrest M Kievit; John R Grierson; Peter A Chiarelli; Robert S Miyaoka; Miqin Zhang; Raymond S Yeung; Satoshi Minoshima; James O Park
Journal:  J Nucl Med       Date:  2014-10-30       Impact factor: 10.057

6.  Characterization of a new highly sensitive immunometric assay for thyroglobulin with reduced interference from autoantibodies.

Authors:  Marianne Nordlund Broughton; Ragnhild Nome; Ingvill Sandven; Elisabeth Paus; Trine Bjøro
Journal:  Tumour Biol       Date:  2015-12-22

7.  Construction, characterisation and kinetics of a single chain antibody recognising the tumour associated antigen placental alkaline phosphatase.

Authors:  P Savage; G Rowlinson-Busza; M Verhoeyen; R A Spooner; A So; J Windust; P J Davis; A A Epenetos
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

8.  In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study.

Authors:  Anna-Karin Haylock; Diana Spiegelberg; Johan Nilvebrant; Karl Sandström; Marika Nestor
Journal:  EJNMMI Res       Date:  2014-03-06       Impact factor: 3.138

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.